Enanta to Present Phase 2 RSV Data at IDWeek 2026
Enanta Pharmaceuticals plans to present Phase 2 data for zelicapavir at IDWeek 2026 on Oct. 22. The data concern symptom resolution, hospitalization and viral load in high-risk adults.
Enanta Pharmaceuticals plans to present Phase 2 data for zelicapavir at IDWeek 2026 on Oct. 22. The data concern symptom resolution, hospitalization and viral load in high-risk adults.